NASDAQ:BCRX BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis $7.22 -0.10 (-1.30%) Closing price 11/20/2026 03:59 PM EasternExtended Trading$7.24 +0.01 (+0.19%) As of 11/20/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BCRX alerts:Sign Up Key Stats Today's Range$7.15▼$7.3950-Day Range$7.23▼$8.7852-Week Range$6.23▼$11.22Volume3.85 million shsAverage Volume5.11 million shsMarket Capitalization$1.86 billionP/E RatioN/ADividend YieldN/APrice Target$20.38Consensus RatingModerate Buy Company Overview BioCryst Pharmaceuticals is a biotechnology company that discovers, develops and commercializes medicines for rare diseases. Founded in 1986, the company is headquartered in Durham, North Carolina, and focuses on small-molecule treatments. Its principal product is ORLADEYO (berotralstat), an oral medicine for preventing attacks of hereditary angioedema, a rare condition that causes episodes of swelling. BioCryst also develops medicines for rare diseases, including candidates targeting hereditary angioedema and complement-mediated disorders. BioCryst serves patients in the United States and other markets through its commercial operations and regional partners. Charlie Gayer is the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More BioCryst Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreBCRX MarketRank™: 2.39789473684 of 5 starsBioCryst Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 505th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBioCryst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialBioCryst Pharmaceuticals has a consensus price target of $20.38, representing about 182.0% upside from its current price of $7.23.Amount of Analyst CoverageBioCryst Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioCryst Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($2.28) to $0.70 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCryst Pharmaceuticals is -5.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCryst Pharmaceuticals is -5.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.17% of the float of BioCryst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 5.09.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently increased by 3.91%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioCryst Pharmaceuticals does not currently pay a dividend.Dividend GrowthBioCryst Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News SentimentN/A News SentimentBioCryst Pharmaceuticals has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for BioCryst Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for BCRX on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat Follows3 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders3.80% of the stock of BioCryst Pharmaceuticals is held by insiders.Percentage Held by Institutions85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioCryst Pharmaceuticals' insider trading history. Receive BCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCRX Stock News HeadlinesBioCryst Pharmaceuticals, Inc. Presents New Real-World Evidence and Clinical Data on ORLADEYO at ACAAI 2026 Annual Scientific MeetingNovember 14, 2026 | marketscreener.comMBioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific MeetingNovember 13, 2026 | globenewswire.comELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet. | Paradigm Press (Ad)BioCryst Pharmaceuticals (BCRX) Raised Its Outlook, Is It Still Below Fair Value?November 7, 2026 | uk.finance.yahoo.comBioCryst Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 6, 2026 | seekingalpha.comBioCryst Pharmaceuticals' Q3 Net Income, Revenue Rise; Increases 2026 Revenue GuidanceNovember 5, 2026 | finance.yahoo.comBioCryst Earnings Call Highlights ORLADEYO GrowthNovember 4, 2026 | tipranks.comBioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call TranscriptNovember 4, 2026 | seekingalpha.comSee More Headlines BCRX Stock Analysis - Frequently Asked Questions How have BCRX shares performed this year? BioCryst Pharmaceuticals' stock was trading at $7.80 at the beginning of the year. Since then, BCRX shares have decreased by 7.4% and is now trading at $7.2250. How were BioCryst Pharmaceuticals' earnings last quarter? BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its quarterly earnings data on Wednesday, November, 4th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. The company's quarterly revenue was up 13.1% on a year-over-year basis. Read the conference call transcript. Who are BioCryst Pharmaceuticals' major shareholders? Top institutional shareholders of BioCryst Pharmaceuticals include State Street Corp (4.78%), Aberdeen Group plc (2.53%), Goldman Sachs Group Inc. (1.65%) and GW&K Investment Management LLC (1.31%). Insiders that own company stock include Alane P Barnes, Helen M Thackray, Anthony Doyle, Nancy J Hutson, Theresa Heggie, Steven K Galson, Alan G Levin, Amy E Mckee, Machelle Sanders and Steve Aselage. View institutional ownership trends. How do I buy shares of BioCryst Pharmaceuticals? Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioCryst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCryst Pharmaceuticals investors own include Palantir Technologies (PLTR), Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Marvell Technology (MRVL), Micron Technology (MU) and Novavax (NVAX). Company Calendar Last Earnings11/04/2026Today11/21/20269th Annual Evercore ISI HealthCONx Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, BCRX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BCRX CIK882796 Webwww.biocryst.com Phone(919) 859-1302Fax919-859-1314Employees435Year Founded1986Price Target and Rating Average Price Target for BioCryst Pharmaceuticals$20.38 High Price Target$32.00 Low Price Target$11.00 Potential Upside/Downside+182.0%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.42) Trailing P/E RatioN/A Forward P/E Ratio10.32 P/E GrowthN/ANet Income$263.86 million Net Margins-37.40% Pretax Margin-36.89% Return on Equity-92.91% Return on Assets66.56% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.64 Sales & Book Value Annual Sales$874.84 million Price / Sales2.12 Cash Flow$1.24 per share Price / Cash Flow5.83 Book Value($1.54) per share Price / Book-4.69Miscellaneous Outstanding Shares257,300,000Free Float247,522,000Market Cap$1.86 billion OptionableOptionable Beta0.55 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:BCRX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | Sponsored“IMPERIUM”: The #1 investment of 2027Could a strange new bio-chip be the most transformative innovation in history? Elon Musk calls it "amazing." A...Banyan Hill Publishing | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.